# Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Study · id `cardio:ct-nct02289963` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02289963](<https://clinicaltrials.gov/study/NCT02289963>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02289963

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

## Technical summary

Registry record NCT02289963. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2017-06-26.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 199 participants (enrolled count; ClinicalTrials.gov record NCT02289963, source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02289963, source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)
- Primary completion: 2016-04 (actual) (ClinicalTrials.gov record NCT02289963, source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)
- Completion: 2016-04 (actual) (ClinicalTrials.gov record NCT02289963, source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)
- Results first posted: 2017-06-26 (ClinicalTrials.gov record NCT02289963, source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)
- Countries: South Korea; Taiwan (ClinicalTrials.gov record NCT02289963, source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02289963-2017-06-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
- Condition: Hypercholesterolemia
- Intervention (Drug): Placebo (for Alirocumab)
- Intervention (Drug): Alirocumab
- Intervention (Drug): Lipid-Modifying Therapy (LMT)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) (`cardio:pubmed-29153823`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab (`cardio:pubmed-30946207`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1cf61292bbbd2827b6293dc7334e5f378a818fcf57863dcf157b8ec043c3c137
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
